Zymeworks (ZYME) Competitors $16.23 +0.39 (+2.43%) As of 03:07 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ZYME vs. PTCT, KRYS, PCVX, ACAD, ACLX, ADMA, ARWR, MENS, MIRM, and MLTXShould you be buying Zymeworks stock or one of its competitors? The main competitors of Zymeworks include PTC Therapeutics (PTCT), Krystal Biotech (KRYS), Vaxcyte (PCVX), ACADIA Pharmaceuticals (ACAD), Arcellx (ACLX), ADMA Biologics (ADMA), Arrowhead Pharmaceuticals (ARWR), Jyong Biotech (MENS), Mirum Pharmaceuticals (MIRM), and MoonLake Immunotherapeutics (MLTX). These companies are all part of the "pharmaceutical products" industry. Zymeworks vs. Its Competitors PTC Therapeutics Krystal Biotech Vaxcyte ACADIA Pharmaceuticals Arcellx ADMA Biologics Arrowhead Pharmaceuticals Jyong Biotech Mirum Pharmaceuticals MoonLake Immunotherapeutics Zymeworks (NYSE:ZYME) and PTC Therapeutics (NASDAQ:PTCT) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, valuation, institutional ownership, risk, profitability, earnings, media sentiment and analyst recommendations. Which has better earnings & valuation, ZYME or PTCT? Zymeworks has higher earnings, but lower revenue than PTC Therapeutics. Zymeworks is trading at a lower price-to-earnings ratio than PTC Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioZymeworks$122.87M9.93-$118.67M-$0.97-16.73PTC Therapeutics$806.78M6.01-$363.30M$6.978.76 Is ZYME or PTCT more profitable? PTC Therapeutics has a net margin of 35.65% compared to Zymeworks' net margin of -182.75%. Zymeworks' return on equity of -23.00% beat PTC Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Zymeworks-182.75% -23.00% -18.04% PTC Therapeutics 35.65%-106.31%30.61% Does the media prefer ZYME or PTCT? In the previous week, PTC Therapeutics had 19 more articles in the media than Zymeworks. MarketBeat recorded 20 mentions for PTC Therapeutics and 1 mentions for Zymeworks. Zymeworks' average media sentiment score of 1.83 beat PTC Therapeutics' score of 0.93 indicating that Zymeworks is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Zymeworks 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive PTC Therapeutics 12 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more risk & volatility, ZYME or PTCT? Zymeworks has a beta of 1.27, suggesting that its share price is 27% more volatile than the S&P 500. Comparatively, PTC Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500. Do analysts prefer ZYME or PTCT? Zymeworks presently has a consensus price target of $21.43, indicating a potential upside of 32.07%. PTC Therapeutics has a consensus price target of $69.00, indicating a potential upside of 13.05%. Given Zymeworks' stronger consensus rating and higher possible upside, analysts plainly believe Zymeworks is more favorable than PTC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Zymeworks 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.90PTC Therapeutics 1 Sell rating(s) 5 Hold rating(s) 9 Buy rating(s) 0 Strong Buy rating(s) 2.53 Do institutionals & insiders believe in ZYME or PTCT? 92.9% of Zymeworks shares are owned by institutional investors. 1.9% of Zymeworks shares are owned by insiders. Comparatively, 5.5% of PTC Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. SummaryZymeworks beats PTC Therapeutics on 9 of the 17 factors compared between the two stocks. Get Zymeworks News Delivered to You Automatically Sign up to receive the latest news and ratings for ZYME and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ZYME and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ZYME vs. The Competition Export to ExcelMetricZymeworksPharmaceutical IndustryMedical SectorNYSE ExchangeMarket Cap$1.22B$852.61M$5.73B$21.44BDividend YieldN/A4.84%5.88%3.49%P/E Ratio-10.791.2277.0329.81Price / Sales9.9326.55527.2151.35Price / CashN/A19.5637.2024.78Price / Book2.456.5813.934.54Net Income-$118.67M-$4.18M$3.30B$999.97M7 Day Performance6.81%0.22%0.87%1.54%1 Month Performance12.99%7.04%4.60%4.77%1 Year Performance31.91%19.50%84.43%14.11% Zymeworks Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ZYMEZymeworks2.4961 of 5 stars$16.23+2.4%$21.43+32.1%+26.6%$1.22B$122.87M-10.79460Positive NewsPTCTPTC Therapeutics3.6938 of 5 stars$56.95-0.5%$69.00+21.2%+76.8%$4.55B$806.78M8.171,410Insider TradeKRYSKrystal Biotech4.9332 of 5 stars$145.20-3.4%$210.38+44.9%-20.5%$4.35B$290.52M29.51210News CoverageAnalyst ForecastPCVXVaxcyte2.1807 of 5 stars$32.41-1.8%$130.00+301.1%-72.7%$4.29BN/A-7.89160Positive NewsACADACADIA Pharmaceuticals4.3209 of 5 stars$25.39+0.5%$28.88+13.7%+48.5%$4.26B$957.80M19.09510ACLXArcellx2.1114 of 5 stars$71.11-2.1%$114.31+60.7%+0.4%$4.03B$107.94M-20.7980Positive NewsADMAADMA Biologics3.5083 of 5 stars$16.42-2.7%$27.67+68.5%-13.8%$4.03B$426.45M19.09530Positive NewsARWRArrowhead Pharmaceuticals4.149 of 5 stars$27.17-6.6%$43.14+58.8%+43.9%$4.02B$3.55M-21.23400Trending NewsInsider TradeAnalyst RevisionMENSJyong BiotechN/A$55.68+6.4%N/AN/A$3.98BN/A0.0031News CoverageHigh Trading VolumeMIRMMirum Pharmaceuticals3.3771 of 5 stars$77.39+1.7%$74.13-4.2%+82.6%$3.82B$336.89M-63.96140Positive NewsMLTXMoonLake Immunotherapeutics2.513 of 5 stars$61.12+2.8%$74.43+21.8%+6.6%$3.82BN/A-21.992 Related Companies and Tools Related Companies PTCT Alternatives KRYS Alternatives PCVX Alternatives ACAD Alternatives ACLX Alternatives ADMA Alternatives ARWR Alternatives MENS Alternatives MIRM Alternatives MLTX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:ZYME) was last updated on 9/17/2025 by MarketBeat.com Staff From Our PartnersHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredStrange crypto pattern discovered by 40-person research teamSomething unusual is happening inside a 40-person crypto research firm. They're helping 8,000+ ordinary peo...Crypto Swap Profits | SponsoredWhy Trump’s “Smart Dollar” could rewrite the rulesMUST SEE: Donald Trump's Radical Overhaul of the U.S. Dollar Congress just approved President Trump's lates...Stansberry Research | SponsoredTrump’s Plan May Undo 1933’s Biggest Financial InjusticeTrump's Reset Can Give Birth To America's Greatest Era Yet A 90-Year cycle may end soon, creating real weal...American Hartford Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Zymeworks Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Zymeworks With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
